Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Debt Repayment

Cash used to repay borrowings during the period.

Oculis Holding AGNASDAQ: OCS

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment grows, but more slowly than its trailing trend

Q1 FY2026 debt repayment of CHF 102K (cash outflow) rose 15.9% year over year, behind the +22.1% change in trailing-twelve-month debt repayment. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +32.9% a year.

Context

  • Debt repayment grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +15.9% toward the trailing-twelve-month pace of +22.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 102K+0.0% QoQ
Last fiscal yearDec 2025
-CHF 373K+36.1% YoY
LTMMar 2026
-CHF 387K+22.1% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.9%——
1 year+36.1%——
3-year CAGR+32.9%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

CHF · from the cash flow

Latest · FY2025
(373K) CHF
Year-over-year change
-36.1%

Debt Repayment vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +22.1% is the 2nd highest of 4, against a peer median of -29.3%.
  • Debt repayment amounts to 76.8% of revenue for OCS, versus a peer median of 12.0%.
OCS Competitors
Debt Repayment for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HROWHarrow Health, Inc.LTM Mar 2026$60.73M USD+103.9%-28.0%22.6%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$3.23M USD-1764.2%+9.5%970.3%
OKYOOKYO Pharma LimitedFY2025$950K USD———
OCSOculis Holding AGLTM Mar 2026CHF 387K CHF+22.1%+32.9%76.8%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$99K USD-29.3%—1.3%
OCULOcular Therapeutix, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding OCS) —-29.3%-9.3%12.0%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.52M)(38.64M)(88.7M)(85.94M)(94.51M)
Depreciation & Amortization235K299K287K406K546K
Deferred Income Tax00000
Stock-Based Compensation328K804K3.61M9.78M16.04M
Change in Working Capital(791K)6M(12.99M)14.16M(70.67K)
Accounts Receivables233K(152K)36K247K1.9M
Inventory00000
Accounts Payables30K3.04M3.73M(1.71M)(1.86M)
Other Working Capital(1.05M)3.11M(16.76M)15.62M(106.97K)
Other Non-Cash Items4.93M6.47M43.95M14.09M15.77M
Operating Cash Flow(13.83M)(25.07M)(53.85M)(47.5M)(62.22M)
Capital Expenditures(28K)(3.55M)(48K)(230K)(287.47K)
Acquisitions (Net)00000
Purchases of Investments00(54.16M)(17.33M)(58.05M)
Sales of Investments00000
Other Investing Activities0(3.48M)000
Investing Cash Flow(28K)(3.55M)(54.21M)(17.56M)(59.38M)
Debt Repayment(98K)(159K)(158K)(274K)(373K)
Common Stock Issued00135.62M53.54M178.95M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(804K)(157K)(5.79M)763K16.77K
Financing Cash Flow55.19M1.71M129.67M54.03M178.6M
Effect of Forex Changes(16K)418K(3.08M)407K174.39K
Net Change in Cash41.33M(26.49M)18.54M(10.62M)57.17M
Free Cash Flow(13.85M)(28.62M)(53.89M)(47.73M)(62.51M)

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.